Bioavailability of ASKP1240 in Healthy Subjects After Intravenous and Subcutaneous Administration of ASKP1240

This study has been completed.
Sponsor:
Collaborator:
Kyowa Hakko Kirin Company, Limited
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )
ClinicalTrials.gov Identifier:
NCT01582399
First received: April 19, 2012
Last updated: December 7, 2012
Last verified: December 2012
  Purpose

The objective of this study is to assess levels of ASKP1240 in the blood after a single dose given intravenously (IV) or as a subcutaneous (SC) injection. The study will determine how the drug behaves inside the body and how it is eliminated from the body by looking at the pharmacokinetics of ASP1240.

In addition, the study will determine the effects of ASKP1240 on the body by looking at its pharmacodynamics (PD) and at the safety and tolerability of ASKP1240 when given by IV or as SC injection.


Condition Intervention Phase
Pharmacokinetics of ASKP1240
Pharmacodynamics of ASKP1240
Healthy Volunteers
Drug: ASKP1240
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: A Phase 1 Single-Dose, Parallel Group, Randomized, Open-Label Study to Determine the Absolute Bioavailability of ASKP1240 After Intravenous and Subcutaneous Administration in Healthy Subjects

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Pharmacokinetic profile: AUClast, AUCinf, and F [ Time Frame: Day 15 to Day 90, ± 3 days ] [ Designated as safety issue: No ]
    Area under the serum concentration- time curve from time 0 up to the last quantifiable concentration (AUClast), Area under the serum concentration- time curve from time 0 extrapolated to infinity (AUCinf), and Absolute bioavailability (F)


Secondary Outcome Measures:
  • Pharmacodynamic profile: CD40 receptor occupancy over time [ Time Frame: Day 15 to Day 90, ± 3 days ] [ Designated as safety issue: No ]
    Cell surface antigen, target of ASKP1240 (CD40), as measured on CD20+ B lymphocytes

  • Pharmacodynamic profile: Total lymphocyte count and peripheral lymphocyte subset quantification [ Time Frame: Day 15 to Day 90, ± 3 days ] [ Designated as safety issue: No ]
    Total lymphocyte count = product of the white blood count (WBC) and percent lymphocytes [from differential]

  • Pharmacokinetics profile: Cmax, Tmax, t1/2, Vz, and CLtot [ Time Frame: Day 15 to Day 90, ± 3 days ] [ Designated as safety issue: No ]
    Maximum concentration (Cmax),Time to attain Cmax (Tmax), Apparent terminal elimination of half-life (t1/2), Apparent volume of distribution ( Vz), and Total body clearance (CLtot)


Enrollment: 24
Study Start Date: February 2012
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A: ASKP1240 intravenous (IV) infusion Drug: ASKP1240
intravenous(IV) infusion and subcutaneous (SC)
Experimental: Arm B: ASKP1240 subcutaneous (SC) Drug: ASKP1240
intravenous(IV) infusion and subcutaneous (SC)

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • The subject weighs at least 50 kg, and has a body mass index (BMI) of 18 to 32 kg/m2, inclusive
  • The female subject must be a) at least two years post-menopausal (defined as at least 2 years without menses) at Screening and a confirmatory follicle stimulating hormone (FSH) level of >40 U/L at Screening) or b) surgically sterile (with documentation provided by a healthcare professional) and not pregnant or lactating at Screening and Day -1. c) If child bearing potential, the subject will be required to use adequate contraception consisting of two forms of birth control (one of which must be a barrier method) until the end of the study or for 90 days after final study drug administration, whichever is longer
  • The male subject agrees to sexual abstinence, is surgically sterile (with documentation provided by a healthcare professional), or is using a medically acceptable method (e.g. spermicide and diaphragm, or spermicide and condom) to prevent pregnancy and agrees to continue using this method until the end of study
  • Male subject agrees to no sperm donation until the end of the study or for 90 days after the conclusion of study drug administration, whichever is longer

Exclusion Criteria:

  • The subject has a history or evidence of any clinically significant (as determined by the Investigator) cardiovascular, endocrine, ophthalmologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary (including asthma or emphysema), neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy (excluding non-melanoma skin cancer)
  • The subject has a history of severe allergic or anaphylactic reactions
  • The subject has a history of consuming more than 14 units of alcoholic beverages (one unit is 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits) per week on average within 6 months prior to Screening or has a history of alcoholism or drug/chemical/substance abuse within past 2 years prior to Screening or the subject tests positive at Screening or Day -1 for alcohol or drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates)
  • The subject has/had a symptomatic, viral, bacterial or fungal (non-cutaneous) infection within 1 week prior to clinic check in on Day -1
  • The subject has a history of thromboembolic or vascular disease especially deep vein thrombosis or pulmonary embolism
  • The subject has used any tobacco-containing products, nicotine or nicotine-containing products in the past 6 months prior to Screening
  • The subject has a supine mean systolic blood pressure < 90 or > 160 mmHg and a mean diastolic blood pressure < 50 or > 90 mmHg, or mean heart rate > 100 beats per minute (bpm), either at Screening or Day -1 (measurements taken in triplicate after subject has been resting in a supine position for a minimum of 5 minutes)
  • The subject is known to be positive for human immunodeficiency virus (HIV) antibody
  • The subject has a positive test for hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or hepatitis B core antibody at Screening
  • The subject has the following at Screening or Day -1:

    1. White blood cell count (WBC) is < 3.5 (109/L) or > upper limit of normal
    2. Absolute neutrophil count (ANC) is < 1.5 (109/L) or > upper limit of normal
    3. Platelet count (PLT) is outside the normal limit
    4. Serum creatinine, total bilirubin, alanine aminotransferase (ALT), or aspartate aminotransferase (AST) are > upper limit of normal
    5. Creatine phosphokinase (CPK) is > 2x times upper limit of normal
    6. International normalized ratio (INR) is > upper limit of normal
    7. Remaining laboratory tests are outside the normal limits and considered by the investigator to be clinically significant with regard to the remaining per-protocol laboratory tests
  • The subject has received any vaccine within 60 days prior to Day -1
  • The subject has received any systemic immunosuppressant agent (e.g., methotrexate) within 6 months prior to Day -1
  • The subject has received any systemic steroid within 2 months prior to Day -1
  • The subject has received any antibody or therapeutic biologic product within 6 months prior to Day -1
  • The subject has used prescription or non-prescription medications (excluding acetaminophen [up to 2 g/day maximum], stable hormone replacement therapy [HRT], and/or nasal steroids/steroid inhaler), or complementary and alternative medicines (CAM) within 14 days or 5 half lives (whichever is longer) prior to Day -1
  • The subject has a positive TB skin test, Quantiferon Gold test or T-SPOT test® at Screening
  • The subject has participated in a previous ASKP1240 study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01582399

Locations
United States, Maryland
Parexel
Baltimore, Maryland, United States, 21225
Sponsors and Collaborators
Astellas Pharma Global Development, Inc.
Kyowa Hakko Kirin Company, Limited
Investigators
Study Director: Medical Director Astellas Pharma Global Development
  More Information

No publications provided

Responsible Party: Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )
ClinicalTrials.gov Identifier: NCT01582399     History of Changes
Other Study ID Numbers: 7163-CL-0106
Study First Received: April 19, 2012
Last Updated: December 7, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Astellas Pharma Inc:
Healthy Volunteers
CD40 receptor occupancy
Co-stimulation blockade
CD40 antigen
Anti-CD40
ASKP1240

ClinicalTrials.gov processed this record on August 28, 2014